1 / 18

TCT, Washington –September 22nd , 2010

Jean-Philippe COLLET* Jean- Sébastien HULOT Ghalia ANZAHA Ana PENA Thomas CHASTRE Johanne SILVAIN Guillaume CAYLA Anne BELLEMAIN-APPAIX Jean- Baptiste VIGNALOU, Farzin BEYGUI Olivier BARTHELEMY Sophie GALIER Vanessa GALOIS Gilles MONTALESCOT

huslu
Download Presentation

TCT, Washington –September 22nd , 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Jean-Philippe COLLET* Jean-Sébastien HULOT Ghalia ANZAHA Ana PENA Thomas CHASTREJohanne SILVAIN Guillaume CAYLA Anne BELLEMAIN-APPAIX Jean-Baptiste VIGNALOU,Farzin BEYGUI Olivier BARTHELEMY Sophie GALIER Vanessa GALOIS Gilles MONTALESCOT *Pitié-Salpêtrière Hospital_URMS_937 75013 Paris-Assistance Publique des Hôpitaux de Paris “CLopidogrel and respOnseVariability Investigation Study”A Randomized Study Comparing the effect of two Clopidogrel LD according to the presence of CYP2C19*2 TCT, Washington –September 22nd , 2010 JP COLLET DISCOSURES: Research Grants : BMS-Sanofi Aventis, Eli Lilly, Medtronic, Cordis ,Johnson&Johnson. Consulting Fees : AstraZeneca, BMS, DaiichiSankyo, Eli Lilly, Sanofi-Aventis. LectureFees: AstraZeneca, BMS, DaiichiSankyo, Eli Lilly, andSanofi-Aventis

  2. STENT THROMBOSIS (n=4905) Odds Ratio, fixed model Bilateral CI, 95% for trials, 95% for MA 2C19*2 2C19*1 10/375 8/1014 8/73 4/186 13/247 11/525 10/680 7/1805 41/1375 30/3530 2C19*2 better 2C19*2 worse Mega et al. (0.26) Collet et al. (0.15) Giusti et al. (0.34) Sibbing et al. (0.24) Total OR 3.45 95% CI: 2.14-5.57, p<0.001, phet=0.78 events / size 0123451020 Odds Ratio J Am Coll Cardiol 2010; 56(2):134-143

  3. Collaborative Meta-analysis: CYP2C19 and Stent Thrombosis in Patients on Clopidogrel Risk Ratio (95% CI) P value Carriers vs Noncarriers 2.81 (1.81-4.37) < .0001 Heterozygotes vs Wild Type 2.67 (1.69-4.22) < .0001 Homozygotes vs Wild Type 3.97 (1.75-9.02) < .001 0.5 1.0 15.0 Risk Lower With CYP2C19 Variant Risk Higher With CYP2C19 Variant N = 5772 Mega JL.American Heart Association; November 2009; Orlando, Florida.

  4. FDA boxed warning • Clopidogrel has diminished effectiveness in individuals based on their CYP2C19 genotype, specifically in those who harbor two CYP2C19 reduced-function alleles • Clinical implications of this genetic-based hazard? • Only early after initiation or during longer-term therapy as well • In the presence of two or at least one CYP2C19 reduced-function allele http://products.sanofi-aventis.us/PLAVIX/PLAVIX.html. Accessed April 20, 2010.

  5. Objectives • To determine whether high dose of clopidogrel can overcome genetic resistance by • comparing the pharmacokinetic (PK) and pharmacodynamic (PD) responses • to two LDs (LD) of clopidogrel (300mg vs. 900mg) • according to carriage of CYP2C19*2 genetic variant

  6. Trial organisation ACTION Study Group (Academic Research Organization, Paris) 1-Coordinating Center: Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris 2-Sponsor: AP-HP (Assistance Publique-Hôpitaux de Paris) 3-Data center, Statistics: Unité Recherche Clinique, Pitié-Salpêtrière Hospital, Paris 4-Funding: Programme Hospitalier de Recherche Clinique (070117)

  7. CLOVIS-2 Study design Young-post MI patients aged <45 years H0 H1 H2 H4 H6 H0 H1 H2 H4 H6 300 mg 300 mg PK PK PK PK PK PK PK PK PK PK Aspirine 75 mg/j ±Clopi 75 mg/ j PD PD PD PD 900 mg 900 mg Phase 1 Phase 2 Wash out 4 weeks

  8. Statistics • Sample size: to demonstrate that 300-mg LD would produce a 40% lower RR-RPA in carriers of CYP2C19*2 vs. non carriers • Inclusion of 45 carriers was required to yield 90% power with an α-risk error of 0.05 and assuming a 20% SD for the difference between regimens • PD was primarily defined as RR-RPA (%) to adjust for pre-treatment status with clopidogrel MD. • The absence of carryover effect was checked and comparison between clopidogrel response across genotype groups and the two LDs tested was evaluated by the Kruskall-Wallis test.

  9. Clovis-2 Flow Chart 566 patients <45 years enrolled (1996 up to 2009) 224 never treated with clopidogrel and 50 without genotype 292 patients <45 years eligible with clinical follow-up 182 declined to participate 51 carriers agreed to participate 43 Heterozygous carriers (wt/*2) were matched with 43 non carriers (wt/wt) 8 Homozygous carriers (*2/*2) were matched with 16 non carriers (wt/wt) 106 patients available for final analysis

  10. Study Endpoints • Relative reduction in residual platelet aggregation (% RPA6hours)–(% RPAbaseline)/(% RPAbaseline)x100 (LTA 20µ Mol ADP) • Area under the plasma concentration (AUC0-6)–time curve of H4 active metabolite (in ng.h/mL) from baseline to six-hours post loading (electrospray liquid chromatography tandem mass spectrometry )

  11. Patients characteristics

  12. Patient characteristics

  13. Baseline Residual Platelet Aggregation p<0.02 for all p<0.04 p=0.16 100 p=0.03 75 µmol/L-induced Residual Platelet Aggregation (%) 50 ADP 20 25 0 wt/wt wt/*2 *2/*2 CYP2C19*2 genotype

  14. Relative Reduction in RPA 900mg-LD 300mg-LD <0.0005 for all* <0.003 for all* 0.03 0.04 0.20 <0.001 100 p<0.001 p=0.0045 mol/L-induced 75 m residual platelet aggregation (%) 50 Relative change of ADP 20 25 0 wt/wt wt/*2 *2/*2 wt/wt wt/*2 *2/*2

  15. Active Metabolites Formation 900mg-LD 300mg-LD p<0.01 for all p<0.001 for all 0.038 0.10 0.153 0.059 50 p=0.012 p=0.02 40 30 0-6 H4 Active metabolite (ng.h/ml) AUC 20 10 0 wt/wt wt/*2 *2/*2 wt/wt wt/*2 *2/*2

  16. High-On Treatment Platelet Reactivity 300mg-LD 900mg-LD 80 <0.0017 for all* <0.0005 for all* 0.024 <0.0004 0.1 <0.0001 p<0.0001 p<0.0001 60 ADL 20 µmol/L-inducedMPA 40 20 0 wt/wt wt/*2 wt/wt wt/*2 *2/*2 *2/*2

  17. PK/PD correlations R2=0.20 for 300mg-LD and 0.23 for 900mg-LD (p<0.0001 for both curves). • significant between AUC0-6 and RR-RPA for both LDs (right-shift of the 900 mg-LD curve) • <10 ng.h/mLgreat variability of PD, not observed with the 900 mg-LD. • >20 ng.h/ml  meaningful inhibitory effect of clopidogrel loading

  18. Conclusions • Co-dominant effect of the 2C19*2 loss-of function allele • High clopidogrel LD overcomes poor response in wt/*2 but not in *2/*2 carriers • *2/*2 carriers deserve alternate therapy • Define a clinical strategy to exploit this pharmacogenetic information to optimize outcomes with clopidogrel

More Related